公开(公告)号：WO2017125406A1

公开(公告)日：2017-07-27

申请号：PCT/EP2017/050932

申请日：2017-01-18

Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ PAUL SABATIER TOULOUSE III

Inventor： ROUET, Philippe ,  SMIH ROUET, Fatima

IPC: G01N33/92 ,  G01N33/68

CPC classification number: G01N33/92 ,  G01N33/6893 ,  G01N2560/00 ,  G01N2800/321

Abstract: The present invention relates to methods of predicting left ventricular remodelling in subjects suffering from hypertension. In particular, the present invention relates to a method of predicting left ventricular remodeling in a subject suffering from hypertension comprising i) determining the mean length of the aliphatic chains of the plasma lipids present in the blood sample obtained from the subject, ii) comparing the mean length determined at step i) with a predetermined reference value and iii) concluding that the subject has or is at risk of having left ventricular remodeling when the mean length determined at step i) is higher than the predetermined reference value or concluding that the subject has not or is not at risk of having left ventricular remodeling when the mean length determined at step i) is lower than the predetermined reference value.

Abstract translation: 本发明涉及预测患有高血压的受试者的左心室重构的方法。 具体而言，本发明涉及预测患有高血压的受试者的左心室重构的方法，其包括i）确定从受试者获得的血液样品中存在的血浆脂质的脂肪链的平均长度，ii） 在步骤i）确定的平均长度与预定的参考值相比较，以及iii）当步骤i）确定的平均长度高于预定参考值时，推断受试者具有左心室重构或存在左心室重构的风险，或者推断受试者 当在步骤i）确定的平均长度低于预定参考值时，没有或没有左心室重构的风险。

公开(公告)号：WO2014089017A1

公开(公告)日：2014-06-12

申请号：PCT/US2013/072768

申请日：2013-12-03

Applicant: VASCULAR BIOSCIENCES ,  MANN, David

Inventor： MANN, David

IPC: C07K7/06

CPC classification number: A61K38/08 ,  A61K45/06 ,  C12Q1/34 ,  G01N33/6893 ,  G01N2333/926 ,  G01N2800/12 ,  G01N2800/321

Abstract: Disclosed are compositions and methods for triggering disease selective macropinocytosis. The compositions can serve as a marker of disease activity and as a trigger of enhanced macropinocytosis in tissues undergoing disease remodeling such as wound healing, cancer, PAH, inflammation, diabetes, Crohn's disease, ulcerative colitis, ankylosing spondylitis, diseases of the endometrium, psoriasis, irritable bowel syndrome, arthritis, fibrotic disorders, interstitial cystitis, autoimmune diseases, asthma, acute lung injury, and adult respiratory distress syndrome. The compositions can also serve as a receptor for disease selective cell penetrating peptides in the cells and extracellular matrix of diseased tissues.

Abstract translation: 公开了用于引发疾病选择性巨噬细胞增多症的组合物和方法。 组合物可以作为疾病活动的标志物，并且作为经历疾病重塑的组织中增强的巨噬细胞增多的触发因素，例如伤口愈合，癌症，PAH，炎症，糖尿病，克罗恩病，溃疡性结肠炎，强直性脊柱炎，子宫内膜疾病，牛皮癣 肠易激综合征，关节炎，纤维化疾病，间质性膀胱炎，自身免疫疾病，哮喘，急性肺损伤和成人呼吸窘迫综合征。 组合物还可以用作疾病选择性细胞穿透肽在患病组织的细胞和细胞外基质中的受体。

公开(公告)号：WO2013159085A1

公开(公告)日：2013-10-24

申请号：PCT/US2013/037557

申请日：2013-04-22

Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATION ,  FELDER, Robin A. ,  CAREY, Robert M. ,  JONES, John E. ,  JOSE, Pedro A. ,  WILLIAMS, Scott M.

Inventor： FELDER, Robin A. ,  CAREY, Robert M. ,  JONES, John E. ,  JOSE, Pedro A. ,  WILLIAMS, Scott M.

IPC: G01N33/50 ,  C12Q1/68 ,  C12N15/11

CPC classification number: C12Q1/6883 ,  A23L33/30 ,  A23V2002/00 ,  C12Q2600/118 ,  C12Q2600/156 ,  G01N33/6893 ,  G01N33/84 ,  G01N2800/321

Abstract: It was determined whether SNPs in SLC4A5 are associated with salt sensitivity of blood pressure (BP). Subjects consumed an isocaloric constant diet with a randomized order of 7 days low Na + (10 mmol/d) and 7 days high Na + (300 mmol/d) intake. Salt sensitivity was defined as a ≥7 mm Hg increase in mean arterial pressure (MAP). 35 polymorphisms in 17 candidate genes were assayed. Association analyses with salt sensitivity revealed three variants that associated with salt sensitivity, two in SLC4A5 (rs7571842, rs10177833; P

Abstract translation: 确定SLC4A5中的SNP是否与血压（BP）的盐敏感性相关。 受试者消耗了一个随机排列为7天低Na +（10 mmol / d）和7天高Na +（300 mmol / d）摄入量的等热恒定饮食。 盐敏感度定义为平均动脉压（MAP）>> 7 mm Hg增加。 测定了17个候选基因中的35个多态性。 具有盐敏感性的关联分析显示与盐敏感性相关的三种变体，两种在SLC4A5（rs7571842，rs10177833; P <0.001）和一种在GRK4（rs1801058; P = 0.020）中）。 还发现与盐摄入量变化相关的血压反应变化与DRD2（rs6276）的SNP相关。 总之，SLC4A5变体与白血病中BP的盐敏感性密切相关，DRD2 SNP是对盐摄入的矛盾反应的标志。

公开(公告)号：WO2010084231A1

公开(公告)日：2010-07-29

申请号：PCT/ES2010/070036

申请日：2010-01-21

Applicant: FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL UNIVERSITARI VALL D'HEBRON, FUNDACIÓ PRIVADA ,  MESEGUER, Anna ,  TORNAVACA LÁZARO, Olga ,  PASCUAL ANGULO, Gloria

Inventor： MESEGUER, Anna ,  TORNAVACA LÁZARO, Olga ,  PASCUAL ANGULO, Gloria

IPC: C12N15/12 ,  A01K67/027 ,  G01N33/50

CPC classification number: G01N33/5088 ,  A01K2217/052 ,  A01K2227/105 ,  A01K2267/035 ,  C12N15/8509 ,  C12N2830/008 ,  G01N2800/321

Abstract: La presente invención se refiere a una construcción génica que comprende el gen de la proteína renal regulada por andrógenos (KAP) de ratón bajo el control de un promotor específico de expresión en tejido renal. Se describen sistemas celulares y animales no humanos modificados genéticamente que comprenden tal construcción y que resultan útiles para la evaluación de los mecanismos involucrados en la hipertensión arterial y diversos tipos de daño nefrológico.

Abstract translation: 本发明涉及包含在肾组织中表达特异性启动子控制的小鼠肾雄激素调节蛋白（KAP）基因的遗传构建。 描述了基因修饰的细胞系统和非人类动物，其包括这样的结构，可用于评估动脉高血压和不同类型的肾脏损伤中涉及的机制。

公开(公告)号：WO2009137091A2

公开(公告)日：2009-11-12

申请号：PCT/US2009002865

申请日：2009-05-08

Applicant: UNIV CALIFORNIA ,  MAHATA SUSHIL ,  TOTA BRUNO ,  O'CONNOR DANIEL ,  BANDYOPADHYAY GUATAM ,  KIRCHMAIR RUDOLF

Inventor： MAHATA SUSHIL ,  TOTA BRUNO ,  O'CONNOR DANIEL ,  BANDYOPADHYAY GUATAM ,  KIRCHMAIR RUDOLF

IPC: C07K14/47 ,  A61K38/17 ,  A61P35/00 ,  G01N33/68

CPC classification number: A61K38/17 ,  C07K14/47 ,  G01N33/6893 ,  G01N2800/321

Abstract: Circulating levels of catestatin (Cts: human chromogranin A352-372) decrease in the plasma of patients with essential hypertension. Genetic ablation of the chromogranin A (Chga) gene in mice increases blood pressure and pre-treatment of Chga-null mice with Cts prevents blood pressure elevation, indicating a direct role of Cts in preventing hypertension. This notable vasoreactivity prompted us to test the direct cardiovascular effects and mechanisms of action of wild-type Cts (WT-Cts) and naturally occurring human variants (G364S-Cts and P370L-Cts) on myocardial and coronary functions. The cardio-inhibitory influence exerted on basal mechanical performance and the counter-regulatory action against beta-adrenergic and ET-1 stimulations, point to Cts as a novel cardiac modulator, able to protect the heart against excessive sympathochromaffin over-activation, e.g. hypertensive cardiomyopathy.

Abstract translation: 原发性高血压患者血浆中catestatin（Cts：人嗜铬粒蛋白A352-372）的循环水平下降。 小鼠中嗜铬粒蛋白A（Chga）基因的遗传消融增加了血压，并且用Cts预处理了Chga-null小鼠，预防了血压升高，表明Cts在预防高血压方面具有直接作用。 这种显着的血管反应性促使我们测试野生型Cts（WT-Cts）和天然存在的人类变体（G364S-Cts和P370L-Cts）对心肌和冠状动脉功能的直接心血管作用和作用机制。 对基础机械性能和对β-肾上腺素能和ET-1刺激的反调控作用的心脏抑制作用指向Cts作为新型心脏调节剂，能够保护心脏免受过度交感神经过度激活，例如， 高血压性心肌病

公开(公告)号：WO2009136112A1

公开(公告)日：2009-11-12

申请号：PCT/FR2009/050661

申请日：2009-04-10

Applicant: ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS ,  MOUTHON, Luc ,  HUMBERT, Marc ,  TAMBY, Mathieu

Inventor： MOUTHON, Luc ,  HUMBERT, Marc ,  TAMBY, Mathieu

IPC: G01N33/68

CPC classification number: G01N33/6854 ,  G01N33/6893 ,  G01N2800/12 ,  G01N2800/321 ,  G01N2800/52 ,  G01N2800/56

Abstract: L'invention concerne un procédé in vitro de détection d'une hypertension artérielle pulmonaire (HTAP), ou d'un risque de développer une HTAP, comprenant la détermination de la présence et/ou de la quantité d'anticorps anti-Ténascine C dans un échantillon biologique provenant d'un patient.

Abstract translation: 本发明涉及用于检测肺动脉高压（PAHT）的体外方法或开发PAHT的风险，其包括测定来自患者的生物样品中抗腱生蛋白C抗体的存在和/或量。

公开(公告)号：WO2009073540A2

公开(公告)日：2009-06-11

申请号：PCT/US2008/084933

申请日：2008-11-26

Applicant: SCHNEIDER, Bryan P. ,  RADOVICH, Milan ,  SLEDGE, George W.

Inventor： SCHNEIDER, Bryan P. ,  RADOVICH, Milan ,  SLEDGE, George W.

IPC: G01N33/50

CPC classification number: G01N33/574 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/142 ,  C12Q2600/156 ,  G01N33/6893 ,  G01N2800/321 ,  G01N2800/50 ,  G01N2800/52

Abstract: Methods for determining whether a patient in at particular risk of hypertension associated with anti-VEGF treatment or has a greater likelihood of benefiting from anti-VEGF therapy by screening a sample isolated from the patient for specific genomic polymorphisms.

Abstract translation: 用于确定是否具有与抗VEGF治疗相关的高血压的特定风险的患者或通过筛选从患者分离的样品用于特异性基因组多态性具有更大可能受益于抗VEGF治疗的方法。

公开(公告)号：WO2007087468A3

公开(公告)日：2008-11-20

申请号：PCT/US2007060270

申请日：2007-01-09

Applicant: CHILDRENS HOSP MEDICAL CENTER ,  MORROW ARDYTHE L ,  MARTIN LISA J ,  NEWBURG DAVID S

Inventor： MORROW ARDYTHE L ,  MARTIN LISA J ,  NEWBURG DAVID S

IPC: A61N1/00 ,  A61K38/18 ,  C07K14/00

CPC classification number: A61K38/2264 ,  A23L33/19 ,  A23L33/40 ,  G01N2800/042 ,  G01N2800/044 ,  G01N2800/065 ,  G01N2800/067 ,  G01N2800/32 ,  G01N2800/321 ,  G01N2800/323 ,  G01N2800/324 ,  A61K2300/00

Abstract: Methods for treating various disorders by orally administering adiponectin or a biologically active fragment thereof are described.

Abstract translation: 描述了通过口服施用脂联素或其生物活性片段治疗各种疾病的方法。

公开(公告)号：WO2008104294A1

公开(公告)日：2008-09-04

申请号：PCT/EP2008/001200

申请日：2008-02-16

Applicant: BAYER HEALTHCARE AG ,  GOLZ, Stefan ,  SUMMER, Holger ,  GEERTS, Andreas ,  WILMEN, Andreas ,  GRUSDAT, Gerda ,  BRÜGGEMEIER, Ulf

Inventor： GOLZ, Stefan ,  SUMMER, Holger ,  GEERTS, Andreas ,  WILMEN, Andreas ,  GRUSDAT, Gerda ,  BRÜGGEMEIER, Ulf

IPC: C12Q1/32 ,  C12Q1/68

CPC classification number: G01N33/6893 ,  G01N33/6875 ,  G01N2333/4712 ,  G01N2333/70567 ,  G01N2800/321 ,  G01N2800/325

Abstract: The invention provides Myh7 as a biomarker for PPARa modulators. The invention relates to the identification of a biomarker or a set of biomarkers or a combination of molecular and clinical markers to monitor or identify or quantify a treatment with a PPARa modulator or a combination of one or more PPARa modulators with other pharmacological compounds.

Abstract translation: 本发明提供Myh7作为PPARa调节剂的生物标志物。 本发明涉及鉴定生物标志物或一组生物标志物或分子和临床标志物的组合，以监测或鉴定或定量用PPARa调节剂或一种或多种PPARα调节剂与其它药理化合物的组合的治疗。

公开(公告)号：WO2008089333A1

公开(公告)日：2008-07-24

申请号：PCT/US2008/051320

申请日：2008-01-17

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN ,  DELGADO, Maria, Carolina ,  PITT, Bertram

Inventor： DELGADO, Maria, Carolina ,  PITT, Bertram

IPC: G01N33/49 ,  G01N33/48

CPC classification number: G01N33/84 ,  G01N33/80 ,  G01N2800/321 ,  G01N2800/322 ,  G01N2800/52

Abstract: The present invention provides methods for measuring, detecting, diagnosing, treating, and researching salt sensitivity and related conditions. In particular, the present invention provides methods for measuring, detecting, diagnosing, treating, and researching salt sensitivity through measuring aberrant red blood cell based potassium efflux levels. In addition, the present invention provides methods for treating conditions involving salt sensitivity (e.g., hypertension), preventing the onset of conditions involving salt sensitivity, identifying individuals at risk for developing salt sensitivity and related conditions, identifying new types of treatment for salt sensitivity and related conditions, and evaluating the effectiveness of treatments for conditions involving salt sensitivity (e.g., hypertension).

Abstract translation: 本发明提供了用于测定，检测，诊断，治疗和研究盐敏感性和相关条件的方法。 特别地，本发明提供了通过测量基于异常红细胞的钾排出水平来测量，检测，诊断，治疗和研究盐敏感性的方法。 此外，本发明提供了治疗涉及盐敏感性（例如高血压）的病症的方法，预防涉及盐敏感性的病症的发病，鉴定处于发展盐敏感性和相关病症风险的个体，鉴定新的盐敏感性治疗类型， 相关条件，并评估治疗对盐敏感性条件（如高血压）的有效性。